MIM
ORIC icon

MetLife Investment Management’s Oric Pharmaceuticals ORIC Stock Holding History

MetLife Investment Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$452K Buy
35,689
+1,719
+5% +$19.5K ﹤0.01% 1802
2025
Q4 		$278K Hold
33,970
– – ﹤0.01% 2109
2025
Q3 		$408K Buy
33,970
+6,898
+25% +$72.6K ﹤0.01% 1905
2025
Q2 		$275K Sell
27,072
-13,784
-34% -$92.5K ﹤0.01% 2009
2025
Q1 		$228K Sell
40,856
-752
-2% -$6.58K ﹤0.01% 2128
2024
Q4 		$336K Buy
41,608
+5,530
+15% +$50.7K ﹤0.01% 2008
2024
Q3 		$370K Hold
36,078
– – ﹤0.01% 1950
2024
Q2 		$255K Buy
36,078
+15,341
+74% +$137K ﹤0.01% 2096
2024
Q1 		$285K Hold
20,737
– – ﹤0.01% 1983
2023
Q4 		$191K Hold
20,737
– – ﹤0.01% 2271
2023
Q3 		$125K Hold
20,737
– – ﹤0.01% 2468
2023
Q2 		$161K Buy
+20,737
New +$118K ﹤0.01% 2402
2022
Q1 		– Sell
-11,317
Closed -$166K – 2757
2021
Q4 		$166K Hold
11,317
– – ﹤0.01% 2171
2021
Q3 		$237K Buy
11,317
+1,866
+20% +$37.8K ﹤0.01% 1985
2021
Q2 		$167K Hold
9,451
– – ﹤0.01% 2262
2021
Q1 		$232K Hold
9,451
– – ﹤0.01% 1974
2020
Q4 		$320K Buy
+9,451
New +$271K ﹤0.01% 1727
2020
Q3 		– Sell
-4,615
Closed -$156K – 2324
2020
Q2 		$156K Buy
+4,615
New +$147K ﹤0.01% 2039

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

MetLife Investment Management's ORIC Position: Q1 2026 in Review

MetLife Investment Management increased its Oric Pharmaceuticals (ORIC) stake by 5.1% in Q1 2026, buying an estimated $19.5K and bringing the position to 35,689 shares worth $452K. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

MetLife Investment Management first reported a position in ORIC in Q2 2020 and has held it in 18 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • MetLife Investment Management held 35,689 shares of Oric Pharmaceuticals worth $452K as of Q1 2026.
  • MetLife Investment Management bought 1,719 Oric Pharmaceuticals shares in Q1 2026, an estimated $19.5K.
  • Oric Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1802 holding.
  • MetLife Investment Management first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.